DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q3 2025

SEC EDGAR SourceSEC Filings

Top Holdings431 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

2.2M$626.6M4.5%$64.83+320.34%
27 qtrssince 2019-Q1
Decreased
0

CRINETICS PHARMACEUTICALS IN

6.5M$270M1.9%$26.60+63.55%
22 qtrssince 2020-Q2
Increased
49

PLANET LABS PBC

14.4M$186.6M1.3%$9.96+28.47%
2 qtrssince 2025-Q2
Increased
78

SITIME CORP

575,208$173.3M1.2%$212.96+37.63%
6 qtrssince 2024-Q2
Increased
55

XENON PHARMACEUTICALS INC

4.2M$167.4M1.2%$27.52+41.91%
23 qtrssince 2020-Q1
Decreased
0
IBNIBN
ADR

ICICI BANK LTD-SPON ADR

5.4M$162M1.2%$19.20+57.46%
27 qtrssince 2019-Q1
Decreased
0

ASTERA LABS INC

825,269$161.6M1.2%$96.63+102.62%
5 qtrssince 2024-Q3
Decreased
0

CAMECO CORP

1.7M$146.5M1.0%$50.09+67.10%
17 qtrssince 2021-Q3
Decreased
0

CURTISS-WRIGHT CORP

268,835$146M1.0%$238.61+127.29%
15 qtrssince 2022-Q1
Decreased
0

RHYTHM PHARMACEUTICALS INC

1.4M$139.7M1.0%$46.42+116.81%
13 qtrssince 2022-Q3
Increased
52

FABRINET

373,436$136.2M1.0%$311.37+16.84%
2 qtrssince 2025-Q2
Increased
54

Guardant Health, Inc.

2.2M$134.5M1.0%$44.83+38.27%
3 qtrssince 2025-Q1
Decreased
0

CREDO TECHNOLOGY GROUP HOLDI

877,110$127.7M0.9%$93.49+56.18%
2 qtrssince 2025-Q2
Decreased
0

URANIUM ENERGY CORP

9.5M$126.6M0.9%$5.98+132.15%
14 qtrssince 2022-Q2
Decreased
0

Sterling Infrastructure, Inc.

357,683$121.5M0.9%$231.51+47.34%
2 qtrssince 2025-Q2
Decreased
0

COMMVAULT SYS INC

638,119$120.5M0.9%$156.34-7.69%
5 qtrssince 2024-Q3
Increased
44

CARVANA CO

317,908$119.9M0.9%$22.23+239.42%
9 qtrssince 2023-Q3
Decreased
0

AXON ENTERPRISE INC

164,990$118.4M0.8%$266.20+169.59%
24 qtrssince 2019-Q4
Decreased
0

CREDICORP LTD

442,153$117.7M0.8%$161.91+65.20%
7 qtrssince 2024-Q1
Increased
42

INTERDIGITAL INC

330,138$114M0.8%$273.96+26.72%
2 qtrssince 2025-Q2
Increased
61
$14B
AUM
431
Positions
Q3 2025
Filing
Rating · 2.0
Quarterly Portfolio Change
+3%Q2'24$10.3B+13%Q3'24$11.6B+4%Q4'24$12.1B-14%Q1'25$10.4B+20%Q2'25$12.5B+12%Q3'25$14B
Activity profile
$ moved · Q3'25
New24%Increased29%Decreased26%Exited21%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.7 years
<1Q13%1-4Q22%1-2Y14%2Y+51%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $14B across 431 positions as of Q3 2025. Top holdings: TSM (4.5%), CRNX (1.9%), PL (1.3%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q3 2025 Summary

Active quarter - 115 new positions, 100 exits, 142 increased. Top move: PL (INCREASED, conviction 78). Portfolio: $14.0B across 431 positions.

Top holdings by portfolio weight

Total AUM$14B
TSM4.49%
CRNX1.93%
PL1.34%
SITM1.24%
XENE1.20%
IBN1.16%
ALAB1.16%
CCJ1.05%
CW1.05%
RYTM1.00%
Other0.98%

Portfolio allocation by GICS sector

Sectors11
Industrials23.46%
Technology21.96%
Healthcare19.53%
Consumer Cyclical9.51%
Financial Services9.44%
Energy4.86%
Basic Materials4.60%
Consumer Defensive4.05%
Communication Services1.87%
Unknown0.43%
Other0.29%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Industrials, Technology, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record66
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used